183 related articles for article (PubMed ID: 37838759)
1. Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia.
Johansson KB; Zimmerman MS; Dmytrenko IV; Gao F; Link DC
Leukemia; 2023 Dec; 37(12):2356-2366. PubMed ID: 37838759
[TBL] [Abstract][Full Text] [Related]
2. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
3. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.
Saygin C; Giordano G; Shimamoto K; Eisfelder B; Thomas-Toth A; Venkataraman G; Ananthanarayanan V; Vincent TL; DuVall A; Patel AA; Chen Y; Tan F; Anthony SP; Chen Y; Shen Y; Odenike O; Teachey DT; Kee BL; LaBelle J; Stock W
Clin Cancer Res; 2023 Aug; 29(16):3151-3161. PubMed ID: 37363966
[TBL] [Abstract][Full Text] [Related]
4. Combination p53 activation and BCL-x
Bell HL; Blair HJ; Jepson Gosling SJ; Galler M; Astley D; Moorman AV; Heidenreich O; Veal GJ; van Delft FW; Lunec J; Irving JAE
Leukemia; 2024 Apr; ():. PubMed ID: 38600316
[TBL] [Abstract][Full Text] [Related]
5. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.
Zhai Y; Tang Q; Fang DD; Deng J; Zhang K; Wang Q; Yin Y; Fu C; Xue SL; Li N; Zhou F; Yang D
Clin Cancer Res; 2023 Jan; 29(1):183-196. PubMed ID: 36240005
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of a G-quadruplex-stabilizing small molecule that synergizes with Navitoclax to induce cytotoxicity in acute myeloid leukemia cells.
Montoya JJ; Turnidge MA; Wai DH; Patel AR; Lee DW; Gokhale V; Hurley LH; Arceci RJ; Wetmore C; Azorsa DO
BMC Cancer; 2019 Dec; 19(1):1251. PubMed ID: 31881855
[TBL] [Abstract][Full Text] [Related]
7. Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia.
Hohtari H; Kankainen M; Adnan-Awad S; Yadav B; Potdar S; Ianevski A; Dufva O; Heckman C; Sexl V; Kytölä S; Mustjoki S; Porkka K
Hemasphere; 2022 Mar; 6(3):e701. PubMed ID: 35233509
[TBL] [Abstract][Full Text] [Related]
8. High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells.
Vernooij L; Bate-Eya LT; Alles LK; Lee JY; Koopmans B; Jonus HC; Schubert NA; Schild L; Lelieveld D; Egan DA; Kerstjens M; Stam RW; Koster J; Goldsmith KC; Molenaar JJ; Dolman MEM
Mol Cancer Ther; 2021 Jun; 20(6):1161-1172. PubMed ID: 33850004
[TBL] [Abstract][Full Text] [Related]
9. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 inhibitor BIIB021 enhances triptolide-induced apoptosis of human T-cell acute lymphoblastic leukemia cells in vitro mainly by disrupting p53-MDM2 balance.
Li M; Zhang X; Zhou WJ; Chen YH; Liu H; Liu L; Yang CM; Qan WB
Acta Pharmacol Sin; 2013 Dec; 34(12):1545-53. PubMed ID: 24241349
[TBL] [Abstract][Full Text] [Related]
11. BCL-xL Targeting to Induce Apoptosis and to Eliminate Chemotherapy-Induced Senescent Tumor Cells: From Navitoclax to Platelet-Sparing BCL-xL PROTACs.
Skwarska A; Konopleva M
Cancer Res; 2023 Nov; 83(21):3501-3503. PubMed ID: 37824434
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.
Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DC; Lock RB
Blood; 2016 Sep; 128(10):1382-95. PubMed ID: 27343252
[TBL] [Abstract][Full Text] [Related]
13. Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors.
Diamanti P; Ede BC; Dace PE; Barendt WJ; Cox CV; Hancock JP; Moppett JP; Blair A
Br J Haematol; 2021 Feb; 192(3):577-588. PubMed ID: 32452017
[TBL] [Abstract][Full Text] [Related]
14. Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL.
Seyfried F; Stirnweiß FU; Niedermayer A; Enzenmüller S; Hörl RL; Münch V; Köhrer S; Debatin KM; Meyer LH
Leukemia; 2022 Apr; 36(4):901-912. PubMed ID: 35031695
[TBL] [Abstract][Full Text] [Related]
15. Combined BCL-2 and PI3K/AKT Pathway Inhibition in
Holz C; Lange S; Sekora A; Knuebel G; Krohn S; Murua Escobar H; Junghanss C; Richter A
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674872
[TBL] [Abstract][Full Text] [Related]
16. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.
Chonghaile TN; Roderick JE; Glenfield C; Ryan J; Sallan SE; Silverman LB; Loh ML; Hunger SP; Wood B; DeAngelo DJ; Stone R; Harris M; Gutierrez A; Kelliher MA; Letai A
Cancer Discov; 2014 Sep; 4(9):1074-87. PubMed ID: 24994123
[TBL] [Abstract][Full Text] [Related]
17. The mtDNA-STING pathway plays an important role in both navitoclax- and S63845-induced autophagy and enhances cell death.
Jia J; Li M; Li Y; Xiao J; Dai H
Cell Biol Toxicol; 2023 Dec; 39(6):2821-2839. PubMed ID: 37002446
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine Signaling.
Shah K; Al Ashiri L; Nasimian A; Ahmed M; Kazi JU
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902436
[TBL] [Abstract][Full Text] [Related]
19. Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors.
Alimova I; Wang D; Danis E; Pierce A; Donson A; Serkova N; Madhavan K; Lakshmanachetty S; Balakrishnan I; Foreman NK; Mitra S; Venkataraman S; Vibhakar R
Int J Oncol; 2022 Mar; 60(3):. PubMed ID: 35179215
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Rooswinkel RW; van de Kooij B; Verheij M; Borst J
Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
